###begin article-title 0
###xml 131 137 <span type="species:ncbi:10090">murine</span>
Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of high-titer IgG autoantibodies directed against nuclear autoantigens. Type I interferon (IFN-I) has been shown to play a pathogenic role in this disease. In the current study, we characterized the role of the IFNAR2 chain of the type I IFN (IFN-I) receptor in the targeting of nucleic acid-associated autoantigens and in B-cell expression of the nucleic acid-sensing Toll-like receptors (TLRs), TLR7 and TLR9, in the pristane model of lupus.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 25 29 25 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 339 347 339 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 29 33 <span type="species:ncbi:10090">mice</span>
Wild-type (WT) and IFNAR2-/- mice were treated with pristane and monitored for proteinuria on a monthly basis. Autoantibody production was determined by autoantigen microarrays and confirmed using enzyme-linked immunosorbent assay (ELISA) and immunoprecipitation. Serum immunoglobulin isotype levels, as well as B-cell cytokine production in vitro, were quantified by ELISA. B-cell proliferation was measured by thymidine incorporation assay.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 70 74 70 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 355 359 355 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 513 517 513 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 529 533 529 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
###xml 359 363 <span type="species:ncbi:10090">mice</span>
###xml 410 414 <span type="species:ncbi:10090">mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 725 729 <span type="species:ncbi:10090">mice</span>
Autoantigen microarray profiling revealed that pristane-treated IFNAR2-/- mice lacked autoantibodies directed against components of the RNA-associated autoantigen complexes Smith antigen/ribonucleoprotein (Sm/RNP) and ribosomal phosphoprotein P0 (RiboP). The level of IgG anti-single-stranded DNA and anti-histone autoantibodies in pristane-treated IFNAR2-/- mice was decreased compared to pristane-treated WT mice. TLR7 expression and activation by a TLR7 agonist were dramatically reduced in B cells from IFNAR2-/- mice. IFNAR2-/- B cells failed to upregulate TLR7 as well as TLR9 expression in response to IFN-I, and effector responses to TLR7 and TLR9 agonists were significantly decreased as compared to B cells from WT mice following treatment with IFN-alpha.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 119 125 <span type="species:ncbi:10090">murine</span>
Our studies provide a critical link between the IFN-I pathway and the regulation of TLR-specific B-cell responses in a murine model of SLE.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 291 292 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 616 617 616 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 765 767 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 804 808 804 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Yaa </italic>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1009 1011 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1087 1091 1087 1091 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1099 1103 1099 1103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1167 1169 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 227 232 <span type="species:ncbi:9606">human</span>
###xml 237 243 <span type="species:ncbi:10090">murine</span>
###xml 808 812 <span type="species:ncbi:10090">mice</span>
###xml 1107 1111 <span type="species:ncbi:10090">mice</span>
Autoantibodies directed against nucleic acid-associated autoantigens are characteristic of the autoimmune disease systemic lupus erythematosus (SLE). The role of the type I interferon (IFN-I) system in the pathogenesis of both human and murine SLE has been studied extensively (reviewed in [1]). Many SLE autoantigens contain nucleic acids and act as endogenous ligands for nucleic acid-sensing Toll-like receptors (TLRs) [2]. Ligation of TLR9 by DNA-associated autoantigens or TLR7 by RNA-associated autoantigens induces secretion of IFN-I by plasmacytoid dendritic cells (PDCs) and activates autoreactive B cells [3-12]. Production of anti-DNA autoantibodies requires TLR9, and the production of anti-ribonucleoprotein (anti-RNP) autoantibodies requires TLR7 [13,14]. A duplication of the TLR7 gene in Yaa mice is sufficient for the induction of autoantibodies against RNA-associated targets [15,16], although some studies suggest that other genes in this locus contribute to autoimmunity in this model [17,18]. TLRs control isotype switching to pathogenic IgG isotypes in SLE as MyD88-/- and TLR9-/- SLE mice lack autoantibodies of the IgG2a and IgG2b subclasses [19].
###end p 11
###begin p 12
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 476 477 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 478 479 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 480 481 480 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 521 525 521 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 838 840 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 841 843 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 871 873 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 931 938 931 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 986 988 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 379 384 <span type="species:ncbi:9606">human</span>
###xml 389 395 <span type="species:ncbi:10090">murine</span>
###xml 525 529 <span type="species:ncbi:10090">mice</span>
###xml 813 818 <span type="species:ncbi:9606">human</span>
###xml 819 827 <span type="species:ncbi:9606">patients</span>
Mice treated with a single intraperitoneal injection of the mineral oil pristane develop a lupus-like disease characterized by the production of autoantibodies directed against many lupus autoantigens, including DNA/histones and components of the U1 small nuclear RNP (snRNP)/Smith antigen (Sm) complex [20]. Autoantibodies directed against this complex are associated with both human and murine lupus [21], and the RNA component can serve as an endogenous ligand for TLR7 [3,5,6,8-10]. Importantly, pristane-treated TLR7-/- mice fail to develop isotype-switched anti-snRNP/Sm autoantibodies [14]. Pristane treatment results in the formation of lipogranulomas and the overexpression of IFN-inducible genes [22], which closely resembles the IFN-I-induced gene expression signature seen in blood cells derived from human patients with SLE [23,24] and is dependent on TLR7 [25]. In addition, treatment with pristane induces apoptosis in vivo, providing a potential source of autoantigens [26], including RNPs and nucleosomes.
###end p 12
###begin p 13
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 939 941 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1088 1090 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1422 1426 1422 1426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
###xml 1301 1305 <span type="species:ncbi:10090">mice</span>
###xml 1426 1430 <span type="species:ncbi:10090">mice</span>
All subtypes of IFN-I bind to the IFN-I receptor (IFNAR), which is composed of two chains: IFNAR1 and IFNAR2. The IFNAR2 chain exists in both transmembrane and soluble isoforms and is critical for ligand binding and signal transduction through the receptor [27,28]. Negative regulators of IFN and other proinflammatory cytokine signaling, including suppressor of cytokine signaling 1 (SOCS1) and the Tyro-3, Axl, and Mer (TAM) receptors, have been shown to associate with, and regulate signaling through, the IFNAR1 chain [29,30]. Signaling through the IFNAR results in activation of the IFN-stimulated gene factor 3 (ISGF3) heterotrimeric complex, composed of STAT1, STAT2, and IFN regulatory factor 9 (IRF9) [31]. We have previously shown that the IFN-I signaling molecules IRF9 and STAT1 are required for the production of IgG autoantibodies in the pristane model and mediate the IFN-I-inducible expression of TLR7 and TLR9 in B cells [32]. We also noted a requirement for these molecules for isotype switching to the pathogenic IgG2a isotype in this model. Nacionales and colleagues [33] demonstrated that mice deficient in the IFNAR1 chain of the receptor fail to develop anti-Sm/RNP and anti-chromatin autoantibodies in the pristane model, although TLR responses were not characterized in these mice. Also, isotype analysis of antigen-specific autoantibodies was not performed. Interestingly, pristane-treated IFNAR1-/- mice produced normal serum levels of IgG2a, and a high percentage developed anti-nuclear autoantibodies (ANAs).
###end p 13
###begin p 14
###xml 127 131 127 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 275 279 275 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 464 468 464 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 576 580 576 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
In the present study, we characterized the role of the IFNAR2 chain of the IFNAR in the pristane model. Pristane-treated IFNAR2-/- mice developed high titers of total serum IgM accompanied by significantly lower levels of the pathogenic IgG2a isotype. Pristane-treated IFNAR2-/- mice failed to develop IgG autoantibodies directed against both RNA- and DNA-associated autoantigens. TLR7 expression and activation by TLR7 agonists were completely abolished in IFNAR2-/- B cells, demonstrating that B-cell activation through TLR7 requires IFNAR2. In addition, B cells from IFNAR2-/- mice failed to upregulate TLR9 expression and activation following incubation with IFN-I. Our results demonstrate a novel role for the IFNAR2 chain of the IFNAR in TLR7- and TLR9-specific B-cell responses and in the production of autoantibodies directed against nucleic acid-associated targets.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice and treatment
###end title 16
###begin p 17
###xml 85 89 85 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 197 201 <span type="species:ncbi:10090">Mice</span>
###xml 304 308 <span type="species:ncbi:10090">mice</span>
BALB/cJ mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). IFNAR2-/- mice on the BALB/c background were provided by Paul J Hertzog (Monash University, Clayton, Australia) [30]. Mice were maintained under standard conditions at the Stanford University Research Animal Facility. Female mice 8 to 10 weeks of age were given a single 0.5 mL intraperitoneal injection of pristane (Sigma-Aldrich, St. Louis, MO, USA) or phosphate-buffered saline (PBS). Sera were collected before injection and at 4-week intervals. Proteinuria was monitored by dipstick analysis using Albustix (Bayer Corp., Elkhart, IN, USA) on a monthly basis. All animal experiments were approved by, and performed in compliance with, the guidelines of the Institutional Animal Care and Use Committee.
###end p 17
###begin title 18
Autoantigen microarrays
###end title 18
###begin p 19
###xml 993 995 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1062 1064 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1251 1253 1239 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1364 1365 1352 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1368 1370 1356 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 163 169 <span type="species:ncbi:9913">bovine</span>
###xml 284 289 <span type="species:ncbi:10090">mouse</span>
###xml 403 407 <span type="species:ncbi:9925">goat</span>
###xml 413 418 <span type="species:ncbi:10090">mouse</span>
###xml 420 423 <span type="species:ncbi:10090">GAM</span>
###xml 932 935 <span type="species:ncbi:10090">GAM</span>
Antigens were printed in ordered arrays on FAST slides (Whatman, now part of GE Healthcare, Piscataway, NJ, USA). Arrays were blocked with PBS containing 3% fetal bovine serum (FBS) and 0.05% Tween-20 (Sigma-Aldrich) overnight at 4degreesC. Arrays were probed with 1:300 dilutions of mouse serum for 1 hour at 4degreesC followed by washing and incubation with a 1:2,000 dilution of cyanine 3-conjugated goat anti-mouse (GAM)-IgG/IgM (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Arrays were scanned using a GenePix 4000B scanner (Molecular Devices Corporation, Sunnyvale, CA, USA). The median pixel intensities of individual features were determined using GenePix Pro version 6.0, and background values were subtracted. The data were expressed as normalized median net digital fluorescence units, representing median values from eight replicate features on each array normalized to the median intensity of eight GAM-Ig features. Significance analysis of microarrays (SAM) [34] was applied to the dataset. A hierarchical clustering algorithm [35] using the uncentered correlation similarity metric and complete linkage method was applied, and results were depicted as a heatmap and dendogram generated using Java Treeview software [36]. A full list of antigens included on the array and detailed protocols are provided [see Additional data file 1] [37].
###end p 19
###begin title 20
Enzyme-linked immunosorbent assays
###end title 20
###begin p 21
###xml 200 204 <span type="species:ncbi:9913">calf</span>
###xml 506 517 <span type="species:ncbi:3704">horseradish</span>
###xml 546 549 <span type="species:ncbi:10090">GAM</span>
###xml 557 560 <span type="species:ncbi:10090">GAM</span>
For anti-single-stranded DNA (anti-ssDNA) enzyme-linked immunosorbent assays (ELISAs), Nunc MaxiSorp plates (Nalgene, a brand of Thermo Scientific Nunc, Rochester, NY, USA) were coated with 10 mug/mL calf thymus DNA (Sigma-Aldrich). For anti-Sm/RNP and anti-ribosomal phosphoprotein P0 (anti-RiboP) ELISAs, plates were coated with 1 mug/mL Sm/RNP or RiboP (Diarect AG, Freiburg, Germany). Wells were incubated with sera diluted 1:250 in PBS containing 3% FBS and 0.05% Tween-20 followed by incubation with horseradish peroxidase (HRP)-conjugated GAM-IgM or GAM-IgG (SouthernBiotech, Birmingham, AL, USA). Tetramethylbenzidine (Pierce, Rockford, IL, USA) was added, and optical density values were determined at 450 nm.
###end p 21
###begin p 22
###xml 81 84 <span type="species:ncbi:10090">GAM</span>
###xml 334 337 <span type="species:ncbi:10090">GAM</span>
###xml 399 404 <span type="species:ncbi:10090">mouse</span>
To determine levels of total serum Ig isotypes, plates were coated with 5 mug/mL GAM-Ig (H+L) (SouthernBiotech) overnight at 4degreesC. Wells were incubated with 1:5,000,000 dilution for IgG, or 1:500,000 dilution for all other isotypes, of sera in PBS containing 3% FBS and 0.05% Tween-20 followed by isotype-specific HRP-conjugated GAM-Ig (SouthernBiotech). Standard curves were constructed using mouse Ig isotype standards (SouthernBiotech), and total levels were determined.
###end p 22
###begin title 23
Real-time quantitative polymerase chain reaction
###end title 23
###begin p 24
###xml 81 85 81 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 265 266 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 333 334 333 334 <sc xmlns:xlink="http://www.w3.org/1999/xlink">L</sc>
###xml 473 476 473 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 1141 1155 1136 1142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;Ct </sup>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 1196 1202 <span type="species:ncbi:10090">murine</span>
Splenocytes were harvested from age- and gender-matched wild-type (WT) and IFNAR2-/- mice. B cells were negatively selected using magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were more than 95% pure, as assessed by flow cytometry (B220+biotin-; data not shown). B cells were cultured in RPMI supplemented with L-glutamine (2 mM), sodium pyruvate (1 mM), nonessential amino acids (0.1 mM), penicillin (100 U/mL), streptomycin (0.1 mg/mL), 2-ME (5 x 10-5 M), and FBS (10%) in the presence or absence of 1,000 IU/mL recombinant IFN-alpha (Calbiochem, now part of EMD Biosciences, Inc., San Diego, CA, USA) for 4 hours. RNA was extracted using RNeasy Mini kit (Qiagen Inc., Valencia, CA, USA). RNA (10 ng) was amplified using one-step QuantiTect SYBR Green reverse transcription-polymerase chain reaction (Qiagen Inc.) and 0.5 muM forward and reverse primers using an Opticon2 continuous fluorescence detector (MJ Research, now part of Bio-Rad Laboratories, Inc., Hercules, CA, USA). The fold change in expression of each transcript normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was determined using the 2-DeltaDeltaCt method. QuantiTect Primer Assay sets for murine TLR7, TLR9, and GAPDH were purchased from Qiagen Inc.
###end p 24
###begin title 25
Proliferation assay
###end title 25
###begin p 26
###xml 295 296 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Splenocytes were harvested at the conclusion of the study 12 months following pristane injection, and B cells were purified as above. Cells were stimulated with 1 muM ODN1826 or 1 mM Loxoribine (InvivoGen, San Diego, CA, USA). Sixteen hours following stimulation, wells were pulsed with 1 muCi [3H]TdR (Amersham, now part of GE Healthcare) and harvested 24 hours following stimulation. Incorporated radioactivity was measured using a betaplate scintillation counter.
###end p 26
###begin title 27
Interleukin-6 production
###end title 27
###begin p 28
B cells were purified, cultured, and stimulated as above. After 24 hours in culture, supernatants were assayed for production of interleukin-6 (IL-6) by sandwich ELISA using a commercially available ELISA kit (BD Pharmingen, San Diego, CA, USA). For IFN-alpha pretreatment studies, B cells were incubated in the presence or absence of 1,000 IU/mL IFN-alpha for 24 hours. TLR ligands were then added as above, and IL-6 concentration in the supernatant was determined 24 hours following stimulation.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
Proteinuria
###end title 30
###begin p 31
###xml 107 111 107 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 513 517 513 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 551 552 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 846 850 846 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lpr </italic>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
To address the role of IFN-I in the development of autoimmunity in the pristane model of SLE, WT and IFNAR2-/- mice were treated with either pristane or PBS as a negative control. WT BALB/c mice treated with pristane develop an immune complex-mediated glomerulonephritis [38]. The development of proteinuria in the mice, a measure of kidney disease, was therefore assessed. Over the course of 12 months, 5 of 10 (50%) pristane-treated WT mice developed proteinuria, whereas none of 10 (0%) pristane-treated IFNAR2-/- mice developed proteinuria (Table 1). These data suggest that IFN-I signaling through IFNAR2 is critical for the development of kidney damage in the pristane model of SLE. Because the development of kidney disease in the pristane model is not as severe as in other spontaneous models of SLE, such as the (NZB x NZW)F1 or the MRL/lpr models, we focused our studies instead on the mechanisms of autoantigen selection and on the role of IFN-I and TLRs in this process.
###end p 31
###begin p 32
Development of proteinuria
###end p 32
###begin p 33
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 37 39 37 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
aProteinuria is at least 300 mg/dL. bP < 0.05 versus wild-type (WT) pristane, Fisher exact test. IFNAR2, interferon-I receptor 2; PBS, phosphate-buffered saline.
###end p 33
###begin title 34
Hypergammaglobulinemia
###end title 34
###begin p 35
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 321 323 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 415 417 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 418 420 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 503 507 499 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 520 521 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 609 613 605 609 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 807 811 803 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 817 819 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 845 849 841 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1080 1084 1076 1080 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
###xml 613 617 <span type="species:ncbi:10090">mice</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
###xml 811 815 <span type="species:ncbi:10090">mice</span>
###xml 849 853 <span type="species:ncbi:10090">mice</span>
###xml 960 964 <span type="species:ncbi:10090">mice</span>
###xml 1084 1088 <span type="species:ncbi:10090">mice</span>
Following pristane treatment, WT mice develop hypergammaglobulinemia characterized by the production of high levels of IgG as well as increased levels of IgM [39]. Importantly, pristane induces the production of high levels of IgG2a, a pathogenic isotype that preferentially binds the activating Fc receptor, FcgammaRIV [40]. IFN-I induces B-cell maturation and promotes isotype switching to all subclasses of IgG [41,42]. We examined the production of immunoglobulin isotypes in pristane-treated IFNAR2-/- mice (Figure 1). Consistent with the known role of IFN-I in isotype switching, pristane-treated IFNAR2-/- mice had significantly higher levels of total serum IgM and significantly lower levels of total serum IgG when compared with pristane-treated WT mice. In contrast to the phenotype seen in IFNAR1-/- mice [33], pristane-treated IFNAR2-/- mice developed significantly lower levels of the pathogenic isotype IgG2a as compared with pristane-treated WT mice. There were no significant differences in the levels of IgG1, IgG2b, or IgG3 between pristane-treated WT and IFNAR2-/- mice.
###end p 35
###begin p 36
###xml 288 290 288 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 329 331 329 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
Serum immunoglobulin levels in pristane-treated mice. Total immunoglobulin levels were measured by enzyme-linked immunosorbent assay in serum obtained 6 months after treatment with phosphate-buffered saline (PBS) or pristane. Mean values with standard deviation are shown for each group. P values were obtained using the Student t test and are displayed above each plot.
###end p 36
###begin p 37
IFNAR2: interferon-I receptor 2; n.s.: not significant; WT: wild-type.
###end p 37
###begin title 38
Autoantibody production
###end title 38
###begin p 39
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 268 272 268 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 684 688 684 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 919 920 919 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1274 1278 1274 1278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 77 83 <span type="species:ncbi:10090">murine</span>
###xml 116 122 <span type="species:ncbi:9606">humans</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 688 692 <span type="species:ncbi:10090">mice</span>
###xml 754 758 <span type="species:ncbi:10090">mice</span>
###xml 1210 1214 <span type="species:ncbi:10090">mice</span>
###xml 1278 1282 <span type="species:ncbi:10090">mice</span>
###xml 1302 1306 <span type="species:ncbi:10090">mice</span>
We have used autoantigen microarrays to profile the autoantibody response in murine models of SLE [32,43-45] and in humans with rheumatic diseases [46,47]. We employed this technique to systematically profile the autoantibody response in pristane-treated WT and IFNAR2-/- mice. Serum from individual mice was used to probe lupus autoantigen microarrays that contained more than 50 candidate SLE autoantigens. A table containing raw median pixel intensity minus background values for all array antigens is provided [see Additional data file 2]. We used the SAM algorithm [34] to determine statistically significant differences in array reactivity between pristane-treated WT and IFNAR2-/- mice followed by hierarchical clustering [35] to order individual mice on the basis of similarity of autoantibody profiles directed against the significant antigens identified by SAM. The results are displayed as a heatmap (Figure 2). SAM identified reactivity to components of two RNA-containing complexes as significantly different between these two groups. Autoantibodies that recognize components of the U1-snRNP complex (Sm/RNP, Sm, BB', U1-A, U1-C, U1-70) and ribosomal P (RiboP) were present in pristane-treated WT mice but were significantly decreased in pristane-treated IFNAR2-/- mice. The two groups of mice separated into completely distinct clusters based on autoantibody reactivity to these autoantigens.
###end p 39
###begin p 40
###xml 442 446 442 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
Autoantibody profiling of pristane-treated mice using autoantigen microarrays. Individual arrays composed of over 50 recombinant or purified antigens were incubated with diluted sera obtained 6 months after pristane treatment. Pairwise significance analysis of microarrays was used to determine antigen features with statistically significant differences in array reactivity between pristane-treated wild-type (WT) and pristane-treated IFNAR2-/- mice (false discovery rate < 0.05, fold change > 3).
###end p 40
###begin p 41
IFNAR2: interferon-I receptor 2; RiboP: ribosomal phosphoprotein P0; Sm: Smith antigen; SmRNP: Smith antigen ribonucleoprotein.
###end p 41
###begin p 42
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 679 683 679 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 722 723 722 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 857 861 857 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 557 561 <span type="species:ncbi:10090">mice</span>
###xml 683 687 <span type="species:ncbi:10090">mice</span>
###xml 861 865 <span type="species:ncbi:10090">mice</span>
We frequently employ autoantigen microarrays as a screening tool to identify autoantibody reactivities using a multiplex platform and rely heavily on statistical algorithms to determine significant differences. Reactivities to all autoantigens are then validated using conventional techniques such as immunoprecipitation, ELISA, and Western blot. WT mice treated with pristane develop high-titer autoantibodies capable of immunoprecipitating the Sm/RNP complex from radiolabeled cell extract [20]. As anticipated, serum autoantibodies from 7 of 10 (70%) WT mice treated with pristane immunoprecipitated components of this complex; however, none of 10 (0%) pristane-treated IFNAR2-/- mice developed these antibodies (Table 2). These results confirm the specific lack of autoantibodies directed against the Sm/RNP complex in serum from pristane-treated IFNAR2-/- mice, confirming the data obtained using autoantigen microarrays.
###end p 42
###begin p 43
Immunoprecipitation of the Smith antigen/ribonucleoprotein complex
###end p 43
###begin p 44
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
aP < 0.005 versus wild-type (WT) pristane, Fisher exact test. IFNAR2, interferon-I receptor 2; PBS, phosphate-buffered saline; Sm/RNP, Smith antigen/ribonucleoprotein.
###end p 44
###begin p 45
###xml 343 347 343 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 575 579 575 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 825 829 825 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 867 871 867 871 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1033 1035 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 1040 1042 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 1134 1136 1134 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 1232 1236 1232 1236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1342 1344 1342 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 1349 1351 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 1427 1429 1427 1429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 1467 1469 1467 1469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 1521 1525 1521 1525 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 579 583 <span type="species:ncbi:10090">mice</span>
###xml 829 833 <span type="species:ncbi:10090">mice</span>
###xml 871 875 <span type="species:ncbi:10090">mice</span>
###xml 1019 1023 <span type="species:ncbi:10090">mice</span>
###xml 1061 1065 <span type="species:ncbi:10090">mice</span>
###xml 1236 1240 <span type="species:ncbi:10090">mice</span>
###xml 1525 1529 <span type="species:ncbi:10090">mice</span>
Our previous studies have demonstrated that the IFN-I downstream signaling molecule, IRF9, was required for the production of IgG autoantibodies directed against the RNA-associated targets, Sm/RNP and RiboP, as well as against the DNA-associated targets, ssDNA and histones. Despite failing to produce IgG autoantibodies, pristane-treated IRF9-/- mice developed significantly higher titers of IgM autoantibodies directed against the two RNA-associated complexes [32]. We therefore examined the production of IgG and IgM autoantibodies directed against these targets in IFNAR2-/- mice (Figure 3). Consistent with the microarray data, IFNAR2 is absolutely required for the development of IgG anti-Sm/RNP (Figure 3a, right panel) and anti-RiboP (Figure 3b, right panel) autoantibodies. In contrast to the phenotype seen for IRF9-/- mice, however, pristane-treated IFNAR2-/- mice do not develop significantly higher titers of IgM autoantibodies directed against either of these targets as compared with pristane-treated WT mice (Figures 3a and 3b, left panels). WT mice treated with pristane develop high titers of IgG anti-ssDNA (Figure 3c, right panel) and anti-histone (Figure 3d, right panel) autoantibodies. Pristane-treated IFNAR2-/- mice develop significantly lower titers of IgG autoantibodies directed against these two targets (Figures 3c and 3d). There are no significant differences in levels of IgM anti-ssDNA (Figure 3c, left panel) or anti-histone (Figure 3d, left panel) between pristane-treated WT and IFNAR2-/- mice. These data demonstrate that IFNAR2 is absolutely required for the development of IgG autoantibodies directed against all of the major antigenic targets in the pristane model of SLE: Sm/RNP, RiboP, and the nucleosome.
###end p 45
###begin p 46
###xml 50 54 50 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 199 202 199 202 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 215 218 215 218 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 231 234 231 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c)</bold>
###xml 252 256 252 256 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 384 386 384 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 432 434 432 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 505 509 505 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
###xml 509 513 <span type="species:ncbi:10090">mice</span>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
###xml 659 663 <span type="species:ncbi:10090">mice</span>
Autoantibody production in pristane-treated IFNAR2-/- mice. Sera obtained 6 months after treatment with pristane or phosphate-buffered saline (PBS) were analyzed for levels of IgM or IgG anti-Sm/RNP (a), anti-RiboP (b), anti-ssDNA (c), or anti-Histone (d) antibodies by enzyme-linked immunosorbent assay. Data are plotted as absorbance values for individual animals minus background. P values were determined using the Mann-Whitney t test for pristane-treated wild-type (WT) versus pristane-treated IFNAR2-/- mice and are displayed above each graph. Closed circles represent serum from PBS-treated mice, and open circles represent serum from pristane-treated mice.
###end p 46
###begin p 47
IFNAR2: interferon-I receptor 2; n.s.: not significant; OD: optical density; RiboP: ribosomal phosphoprotein P0; Sm/RNP: Smith antigen/ribonucleoprotein; ssDNA: single-stranded DNA.
###end p 47
###begin title 48
Toll-like receptor expression
###end title 48
###begin p 49
###xml 100 102 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 324 326 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 404 408 400 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 420 424 416 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 579 581 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 732 734 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 870 874 862 866 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1089 1091 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 79 84 <span type="species:ncbi:9606">human</span>
###xml 228 234 <span type="species:ncbi:10090">murine</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 654 658 <span type="species:ncbi:10090">mice</span>
###xml 874 878 <span type="species:ncbi:10090">mice</span>
PDC secretion of IFN-alpha has been shown to enhance the expression of TLR7 in human naive B cells [48]. In support of this study, we have previously reported a critical role for the IFN-I signaling components IRF9 and STAT1 in murine B-cell expression of TLR7 as well as in the IFN-I-mediated induction of TLR9 expression [32]. We examined the mRNA expression levels of these TLRs in B cells from IFNAR2-/- mice. IFNAR2-/- B cells expressed lower basal levels of TLR7 when compared with WT B cells; however, there was no significant difference in the expression of TLR9 (Figure 4a). As demonstrated previously, the expression of TLR7 in B cells from WT mice was induced more than 20-fold following treatment with IFN-alpha (Figure 4b). This induction of TLR7 expression was completely dependent on IFNAR2 as there was no change in TLR7 expression in B cells from IFNAR2-/- mice following treatment with IFN-alpha. The expression of TLR9 in WT B cells was upregulated approximately 3-fold upon treatment with IFN-alpha and this upregulation was also completely dependent on IFNAR2 (Figure 4b). IFNAR2 is therefore required for the induction of TLR7 and TLR9 expression in B cells in response to IFN-alpha and for normal basal levels of B-cell TLR7 expression.
###end p 49
###begin p 50
###xml 57 61 57 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 70 74 70 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 125 129 125 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 238 242 238 242 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 407 409 403 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 450 452 446 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
Expression of Toll-like receptors TLR7 and TLR9 in IFNAR2-/- B cells. (a) B cells were purified from wild-type (WT) or IFNAR2-/- mice using magnetic beads. RNA was extracted and the relative mRNA expression of TLR7 and TLR9 was measured. (b) Purified B cells were cultured in the presence or absence of interferon-alpha (IFN-alpha). RNA was extracted and the relative expression TLR7 and TLR9 was measured. P values were determined using the Student t test.
###end p 50
###begin p 51
IFNAR2: interferon-I receptor 2; n.s.: not significant.
###end p 51
###begin title 52
Toll-like receptor activation
###end title 52
###begin p 53
###xml 79 83 79 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 169 173 169 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 284 288 284 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 641 645 641 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 645 649 <span type="species:ncbi:10090">mice</span>
We next examined the functional ability of B cells from pristane-treated IFNAR2-/- mice to respond to TLR7 and TLR9 agonists. B cells from pristane-treated WT and IFNAR2-/- mice were cultured with the TLR7 agonist, Loxoribine, or the CpG motif-containing TLR9 agonist, ODN1826. IFNAR2-/- B cells proliferated significantly less (Figure 5a) and secreted significantly less IL-6 (Figure 5b) versus WT B cells in response to Loxoribine. Consistent with basal expression data, there were no significant differences in proliferation (Figure 5a) or IL-6 secretion (Figure 5b) in response to the TLR9 agonist in B cells from pristane-treated IFNAR2-/- mice.
###end p 53
###begin p 54
###xml 57 61 57 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activation of Toll-like receptors TLR7 and TLR9 in IFNAR2<sup>-/- </sup>mice</bold>
###xml 67 71 67 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 139 143 139 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 379 383 375 379 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 542 546 538 542 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 776 778 768 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 819 821 811 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
Activation of Toll-like receptors TLR7 and TLR9 in IFNAR2-/- mice. (a) B cells were purified from pristane-treated wild-type (WT) or IFNAR2-/- mice, and proliferation in response to Loxoribine or ODN1826 was measured. Data are represented as the difference in mean counts per minute (cpm) of stimulated and unstimulated triplicate wells (Delta cpm) + standard error of the mean. (b) B cells were purified as above and the concentration of interleukin-6 (IL-6) in the supernatant was measured following stimulation with Loxoribine or ODN1826. (c) B cells were purified as above and were cultured in the presence or absence of interferon-alpha (IFN-alpha) for 24 hours before treatment with Loxoribine or ODN1826. The concentration of IL-6 in the supernatant was then measured. P values were determined using the Student t test.
###end p 54
###begin p 55
IFNAR2: interferon-I receptor 2; n.s.: not significant; ODN: oligodeoxynucleotide.
###end p 55
###begin p 56
###xml 255 257 243 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 301 303 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 347 351 335 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 474 476 458 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 529 531 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 549 553 529 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 646 648 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 765 769 737 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 782 784 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
Because IFN-alpha upregulated B-cell expression of TLR7 and TLR9, we examined the ability of IFN-alpha to enhance B-cell activation by TLR ligands. B cells from WT mice pretreated with IFN-alpha secreted significantly more IL-6 than untreated WT B cells (P = 0.0001) in response to Loxoribine (Figure 5c). In striking contrast, B cells from IFNAR2-/- mice secreted very low levels of IL-6 in response to Loxoribine, and this was not enhanced by pretreatment with IFN-alpha (P < 0.0001 versus IFN-alpha-treated WT B cells, Figure 5c). Although IFNAR2-/- B cells responded normally to the TLR9 agonist in the absence of exogenous IFN-alpha (Figure 5b), the IFN-alpha-mediated enhancement of B-cell activation by ODN1826 was completely abolished in B cells from IFNAR2-/- mice (Figure 5c). These studies indicate that IFN-I signaling through IFNAR2 mediates both the expression of, and activation through, nucleic acid-sensing TLRs in B cells.
###end p 56
###begin title 57
Discussion
###end title 57
###begin p 58
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 581 585 581 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 614 618 614 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 892 896 892 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1510 1514 1498 1502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1756 1759 1744 1747 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1766 1769 1754 1757 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1781 1785 1769 1773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1816 1820 1804 1808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lpr </italic>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
###xml 585 589 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 896 900 <span type="species:ncbi:10090">mice</span>
###xml 1072 1076 <span type="species:ncbi:10090">mice</span>
###xml 1514 1518 <span type="species:ncbi:10090">mice</span>
Previously, we have demonstrated that the IFN-I signaling molecules, IRF9 and STAT1, were required for the production of IgG autoantibodies in the pristane model and for the high expression levels of TLR7 and TLR9 following treatment with IFN-I in B cells [32]. Here, we describe the autoantibody profile and TLR-dependent B-cell response in SLE mice genetically deficient in the IFNAR2 chain of the IFNAR. Autoantibody profiling using autoantigen microarrays in combination with conventional techniques to confirm the array results revealed that, similar to the phenotype for IRF9-/- mice, pristane-treated IFNAR2-/- mice specifically lacked IgG autoantibodies directed against all of the major targets in the pristane model. These targets included components of the RNA-associated complexes Sm/RNP and RiboP as well as the DNA-associated autoantigens ssDNA and histones. B cells from IFNAR2-/- mice exhibited defects in the expression of TLR7 as well as in responses to TLR7 agonists in the absence of exogenous IFN-alpha. Upon treatment with IFN-alpha, B cells from WT mice upregulated TLR7 expression over 20-fold, upregulated TLR9 expression approximately 3-fold, and secreted significantly higher levels of IL-6 in response to stimulation through either TLR7 or TLR9. In the absence of IFNAR2, however, this IFN-alpha-mediated enhancement of TLR7 and TLR9 expression and activation was completely abolished. TLR7 responses, in particular, were almost undetectable. Taken together with our studies in IRF9-/- mice, the results of these experiments demonstrate a critical role for the IFN-I pathway in the activation of B cells and subsequent autoantibody production in response to TLR agonists. We are currently in the process of backcrossing the IRF9-/-, STAT1-/-, and IFNAR2-/- genetic deletions onto the MRL/lpr background in order to more carefully assess the role of this molecule in the development of lupus nephritis and to determine whether other major autoantigen classes are still targets of autoantibodies.
###end p 58
###begin p 59
###xml 83 87 83 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 97 101 97 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 157 161 157 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 339 343 339 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 519 523 519 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 624 628 624 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 731 735 723 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 801 805 793 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 814 816 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 851 855 843 847 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 996 1000 984 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1016 1018 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 1061 1065 1049 1053 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1126 1130 1110 1114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1192 1196 1176 1180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1235 1237 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1288 1292 1272 1276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1394 1395 1374 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 2070 2074 2050 2054 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 2199 2203 2179 2183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 2266 2270 2246 2250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 2431 2435 2411 2415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 161 165 <span type="species:ncbi:10090">mice</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
###xml 523 527 <span type="species:ncbi:10090">mice</span>
###xml 2074 2078 <span type="species:ncbi:10090">mice</span>
###xml 2203 2207 <span type="species:ncbi:10090">mice</span>
###xml 2270 2274 <span type="species:ncbi:10090">mice</span>
###xml 2435 2439 <span type="species:ncbi:10090">mice</span>
There are three very important differences between the phenotypes observed for IRF9-/- and IFNAR2-/- mice in the pristane model. First, pristane-treated IRF9-/- mice developed significantly higher titers of IgM autoantibodies directed against the RNA-associated autoantigens Sm/RNP and RiboP [32]. This phenotype was not observed in IFNAR2-/- mice as there was no significant difference in levels of IgM autoantibodies directed against these two targets versus WT mice treated with pristane or versus PBS-treated IFNAR2-/- mice (Figures 3a and 3b). Second, although the expression of TLR7 was significantly decreased in IRF9-/- B cells versus WT B cells following treatment with IFN-alpha, TLR7 expression in IFN-alpha-treated IRF9-/- B cells was actually significantly increased versus untreated IRF9-/- B cells [32]. This was not the case for IFNAR2-/- B cells as TLR7 expression was not induced, even at lower levels, following treatment with IFN-alpha (not significant versus untreated IFNAR2-/- B cells, Figure 5b). The small increase in expression in IRF9-/- B cells has functional implications as IFN-alpha-treated IRF9-/- B cells secreted significantly more IL-6 versus untreated IRF9-/- B cells in response to a TLR7 agonist [32], whereas virtually no IL-6 was secreted by IFNAR2-/- B cells in response to a TLR7 agonist, regardless of whether they were treated with IFN-alpha (Figure 5). Our studies therefore suggest that the IRF9-independent induction of TLR7 by IFN-I may be sufficient to drive the partial activation of B cells, which results in the production of high levels of IgM autoantibodies directed against RNA-associated targets. It is not sufficient, however, to drive the full activation of these cells to differentiate into isotype-switched IgG-secreting plasma cells. On the other hand, by inhibiting the IFN-I response further upstream through the IFNAR2 chain of the receptor, we observed a complete block in B-cell expression of TLR7, activation through TLR7, and autoantibody production directed against RNA-associated targets. Third, IRF9-/- mice treated with pristane developed fatal plasmacytomas as early as 6 months following pristane injection, whereas no IFNAR2-/- mice developed this phenotype. Because the majority of the IRF9-/- mice developed this fatal condition prior to the conclusion of the study, we were unable to accurately assess kidney damage in this strain. As none of the IFNAR2-/- mice developed any signs of proteinuria over the course of the 12-month study, we can now conclude that IFN-I signaling is crucial for the development of end-organ pathogenesis in this model.
###end p 59
###begin p 60
###xml 45 49 45 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 102 106 102 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 343 347 343 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 426 430 426 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 443 444 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 596 600 596 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 628 632 628 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 802 806 802 806 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 841 845 841 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 946 955 946 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 997 1004 997 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 521 525 <span type="species:ncbi:10090">mice</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 632 636 <span type="species:ncbi:10090">mice</span>
###xml 806 810 <span type="species:ncbi:10090">mice</span>
###xml 845 849 <span type="species:ncbi:10090">mice</span>
The block in isotype switching to IgG in IRF9-/- mice was restricted to TLR-dependent antigens as IRF9-/- mice immunized with ovalbumin (OVA) in complete Freund's adjuvant, a strong stimulus, mounted an effective IgG anti-OVA response [32]. Although higher levels of IgM-specific autoantibodies were not observed in the pristane-treated IFNAR2-/- mice, total serum levels of IgM were highly elevated in pristane-treated IFNAR2-/- mice (Figure 1), suggesting that there may be defects in isotype switching to IgG in these mice. Total serum IgM levels were also increased in pristane-treated IFNAR1-/- mice [33]. Studies in IFNAR1-/- mice have revealed that IFN-I promotes isotype switching to all subtypes of IgG [41,42], although in the pristane model, total serum levels of IgG2a were normal in IFNAR1-/- mice [33]. Future studies in IFNAR2-/- mice are therefore aimed at investigating the role that IFNAR2 plays in isotype switching in B cells in vitro and in response to different TLR agonists in vivo.
###end p 60
###begin p 61
###xml 270 272 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 288 292 284 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 375 377 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 378 380 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 538 540 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 767 771 759 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 843 851 835 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 852 854 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 936 940 928 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 996 1000 988 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1010 1014 1002 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1106 1110 1098 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1271 1273 1263 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
###xml 771 775 <span type="species:ncbi:10090">mice</span>
###xml 940 944 <span type="species:ncbi:10090">mice</span>
###xml 1014 1018 <span type="species:ncbi:10090">mice</span>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
Two key negative regulators of TLR responses have been found to physically associate with the IFNAR1 chain of the receptor: SOCS1 and the TAM receptors, which include Tyro, Axl, and Mer. The induction of the SOCS proteins by IFN-alpha is dependent on the TAM receptors [29] and both SOCS1-/- and TAM receptor triple-knockout mice develop spontaneous lupus-like autoimmunity [49,50]. The expressions of the TAM receptors themselves are upregulated by IFN and TLR signaling. Both of these pathways require the presence of IFNAR1 and STAT1 [29]. Therefore, in addition to mediating signals initiated by IFN-alpha, IFNAR1 is critical for TAM receptor-mediated negative regulation of pleiotropic TLR responses. The function of TAM receptors has not been assessed in IFNAR2-/- mice, although signals transduced by IFNAR2 are not influenced by SOCS1 in vivo [30]. We hypothesize that the lack of negative regulatory molecule function in IFNAR1-/- mice may result in phenotypic differences between IFNAR1-/- and IFNAR2-/- mice in models of autoimmunity. Such differences are notable in the pristane model as IFNAR1-/- mice developed high serum titers of the pathogenic IgG2a isotype and high ANA titers, although the identity of the autoantigen driving this response is unknown [33]. It will therefore be critical to assess the function of TAM receptors and the differential roles of IFNAR1 and IFNAR2 in the development of autoimmunity.
###end p 61
###begin p 62
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lpr </italic>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 758 762 754 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lpr </italic>
###xml 1070 1072 1066 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1335 1337 1331 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 1381 1390 1377 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1394 1401 1390 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1449 1451 1445 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1529 1531 1525 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 13 19 <span type="species:ncbi:10090">murine</span>
###xml 187 193 <span type="species:ncbi:10090">murine</span>
###xml 482 487 <span type="species:ncbi:9606">human</span>
###xml 494 502 <span type="species:ncbi:9606">patients</span>
###xml 762 766 <span type="species:ncbi:10090">mice</span>
###xml 1050 1055 <span type="species:ncbi:9606">human</span>
###xml 1060 1068 <span type="species:ncbi:9606">patients</span>
###xml 1282 1286 <span type="species:ncbi:10090">mice</span>
###xml 1518 1523 <span type="species:ncbi:9606">human</span>
###xml 1626 1631 <span type="species:ncbi:9606">human</span>
Unlike other murine models of SLE, such as the MRL/lpr and the (NZB x NZW)F1 spontaneous models, the pristane model is ideally suited for studying the IFN-I pathway in the development of murine SLE. This is true for several reasons. First, pristane injection has been shown to induce the accumulation of an IFN-producing Ly6C-high monocyte population [51], which drives the subsequent expression of IFN-I-inducible genes [22]. These same genes are overexpressed in blood cells from human lupus patients, and expression of these genes correlates with the production of anti-nucleoprotein autoantibodies [23,24,52-54]. In contrast, the expression of IFN-gamma-regulated, but not IFN-I-regulated, genes is enhanced in both splenocyte subsets and kidneys of MRL/lpr mice, suggesting that the type II IFN pathway rather than the IFN-I pathway plays the dominant pathogenic role in the development of autoimmunity in this model. Second, the spectrum of autoantibodies produced upon pristane treatment represents several clinically assayed specificities in human SLE patients [55]. The (NZB x NZW)F1 model is inadequate to study the anti-RNP response as these animals do not develop autoantibodies directed against RNA-associated autoantigens, although pristane treatment of (NZB x NZW)F1 mice induces the production of these autoantibodies [56]. Finally, pristane induces apoptosis both in vitro and in vivo, providing a potential source of autoantigens [26]. Defects in clearance of apoptotic debris is a common feature of human SLE [57]. Therefore, disease pathogenesis in the pristane model recapitulates several key features of human SLE, including kidney pathology, IFN-I pathway activation, autoantibody production, and induction of apoptosis.
###end p 62
###begin title 63
Conclusions
###end title 63
###begin p 64
###xml 157 164 157 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 377 384 377 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1024 1032 1024 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 595 600 <span type="species:ncbi:9606">human</span>
###xml 601 609 <span type="species:ncbi:9606">patients</span>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
###xml 923 928 <span type="species:ncbi:9606">human</span>
In summary, our data demonstrate a novel role for the IFNAR2 in TLR7- and TLR9-specific B-cell responses and in the generation of IgG autoantibody responses in vivo. We propose that the production of IFN-I by DCs upon pristane treatment [22] induces the expression of TLR7 and TLR9 in B cells, resulting in the activation of autoreactive B cells and in autoantibody production in vivo. This response is completely dependent on signaling through IFNAR2. Our results provide further support for the development of specific inhibitors of TLR7, TLR9, and IFN-I signaling for the treatment of SLE in human patients and suggest that patients may be selected for such therapeutic approaches and monitored for response to therapy based on the targeting of subsets of nucleic acid-associated autoantigens. These studies are of particular importance given that IFN-I and TLR inhibitors are already being tested in SLE in early-phase human clinical trials. Our studies provide a crucial link between the IFN-I system and TLR signaling in vivo and suggest that IFN-I is upstream of TLRs in the loss of B-cell tolerance to nucleic acid-associated autoantigens in SLE.
###end p 64
###begin title 65
Abbreviations
###end title 65
###begin p 66
###xml 85 91 <span type="species:ncbi:9913">bovine</span>
###xml 99 102 <span type="species:ncbi:10090">GAM</span>
###xml 107 111 <span type="species:ncbi:9925">goat</span>
###xml 117 122 <span type="species:ncbi:10090">mouse</span>
###xml 193 204 <span type="species:ncbi:3704">horseradish</span>
ANA: anti-nuclear autoantibody; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GAM-Ig: goat-anti-mouse-immunoglobulin; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HRP: horseradish peroxidase; IFN-I: type I interferon; IFNAR: interferon-I receptor; IL-6: interleukin-6; IRF9: interferon regulatory factor 9; ODN: oligodeoxynucleotide; OVA: ovalbumin; PBS: phosphate-buffered saline; PDC: plasmacytoid dendritic cell; RiboP: ribosomal phosphoprotein P0; RNP: ribonucleoprotein; SAM: significance analysis of microarrays; SLE: systemic lupus erythematosus; Sm: Smith antigen; snRNP: small nuclear ribonucleoprotein; SOCS1: suppressor of cytokine signaling 1; ssDNA: single-stranded DNA; TAM: Tyro-3, Axl, and Mer; TLR: Toll-like receptor; WT: wild-type.
###end p 66
###begin title 67
Competing interests
###end title 67
###begin p 68
###xml 148 153 <span type="species:ncbi:111540">Aliso</span>
In the past 5 years, PJU has served as a consultant to Centocor, Inc. (Horsham, PA, USA), Biogen Idec (Cambridge, MA, USA), Avanir Pharmaceuticals (Aliso Viejo, CA, USA), Amgen (Thousand Oaks, CA, USA), UCB (Brussels, Belgium), Argos Therapeutics, Inc. (Durham, NC, USA), AstraZeneca (London, UK), CoMentis, Inc. (South San Francisco, CA, USA), Gilead Sciences, Inc. (Foster City, CA, USA), REGiMMUNE Corporation (Mountain View, CA, USA), Johnson & Johnson (New Brunswick, NJ, USA), and Genentech, Inc. (South San Francisco, CA, USA). PJU was a member of the scientific advisory boards of Monogram Biosciences, Inc. (South San Francisco, CA, USA) and XDx, Inc. (Brisbane, CA, USA) and is a cofounder of and consultant to Bayhill Therapeutics (San Mateo, CA, USA). DLT is currently an employee of Genentech, Inc. The other authors declare that they have no competing interests.
###end p 68
###begin title 69
Authors' contributions
###end title 69
###begin p 70
###xml 534 538 534 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
DLT conceived of the study idea, contributed to the experimental design, performed experiments, participated in the writing of the manuscript and data interpretation, and helped to perform array studies and conduct statistical analysis. KLG contributed to the experimental design and assisted with animal studies. LYL monitored survival and proteinuria in the mice and assisted with animal studies. IB helped to perform array studies and conduct statistical analysis. PJH contributed to the experimental design and supplied the IFNAR2-/- mice. PJU assisted with conception of the study idea and participated in its design, data analysis, and the writing of the manuscript. All authors read and approved the final manuscript.
###end p 70
###begin title 71
Supplementary Material
###end title 71
###begin title 72
Additional data file 1
###end title 72
###begin p 73
A table providing a description of the autoantigens used on the protein microarrays, which includes the source, origin, tag information, and known disease associations for each antigen.
###end p 73
###begin p 74
Click here for file
###end p 74
###begin title 75
Additional data file 2
###end title 75
###begin p 76
A table containing raw median pixel intensity minus background values for all array antigens and samples used in this study.
###end p 76
###begin p 77
Click here for file
###end p 77
###begin title 78
Acknowledgements
###end title 78
###begin p 79
The authors thank Michael G Kattah, Alvina D Chu, Cindy Limb, Peggy P Ho, and other members of the Utz laboratory for technical assistance and helpful discussions. This work was supported by National Institutes of Health (NIH) grants AI50854, AI50865, AR49328, and U19-DK61934; NHLBI Proteomics contract N01-HV-28183; a grant from the Northern California Chapter of the Arthritis Foundation; a Dana Foundation grant; and a gift from the Floren Family Foundation to PJU. DLT is the recipient of a National Science Foundation Graduate Research Fellowship and a P.E.O. Sisterhood Scholar Award. KLG is the recipient of an NIH National Research Service Award Fellowship (AI-10663-02).
###end p 79
###begin article-title 80
Type I interferon in systemic lupus erythematosus and other autoimmune diseases
###end article-title 80
###begin article-title 81
Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease
###end article-title 81
###begin article-title 82
U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7
###end article-title 82
###begin article-title 83
Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA
###end article-title 83
###begin article-title 84
"Endogenous adjuvant" activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60
###end article-title 84
###begin article-title 85
Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8
###end article-title 85
###begin article-title 86
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9
###end article-title 86
###begin article-title 87
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement
###end article-title 87
###begin article-title 88
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus
###end article-title 88
###begin article-title 89
U1 RNA induces innate immunity signaling
###end article-title 89
###begin article-title 90
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
###end article-title 90
###begin article-title 91
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 55 60 <span type="species:ncbi:9606">human</span>
Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production
###end article-title 91
###begin article-title 92
###xml 120 126 <span type="species:ncbi:10090">murine</span>
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus
###end article-title 92
###begin article-title 93
###xml 105 111 <span type="species:ncbi:10090">murine</span>
Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis
###end article-title 93
###begin article-title 94
###xml 58 64 <span type="species:ncbi:10090">murine</span>
A Tlr7 translocation accelerates systemic autoimmunity in murine lupus
###end article-title 94
###begin article-title 95
Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication
###end article-title 95
###begin article-title 96
Evidence for genes in addition to Tlr7 in the Yaa translocation linked with acceleration of systemic lupus erythematosus
###end article-title 96
###begin article-title 97
Yaa autoimmune phenotypes are conferred by overexpression of TLR7
###end article-title 97
###begin article-title 98
TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE
###end article-title 98
###begin article-title 99
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane
###end article-title 99
###begin article-title 100
Antibodies to snRNPs in systemic lupus erythematosus
###end article-title 100
###begin article-title 101
Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane)
###end article-title 101
###begin article-title 102
Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus
###end article-title 102
###begin article-title 103
Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus
###end article-title 103
###begin article-title 104
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus
###end article-title 104
###begin article-title 105
Induction of apoptosis by the hydrocarbon oil pristane: implications for pristane-induced lupus
###end article-title 105
###begin article-title 106
###xml 12 18 <span type="species:ncbi:10090">murine</span>
The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties
###end article-title 106
###begin article-title 107
###xml 95 101 <span type="species:ncbi:10090">murine</span>
Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2
###end article-title 107
###begin article-title 108
TAM receptors are pleiotropic inhibitors of the innate immune response
###end article-title 108
###begin article-title 109
Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity
###end article-title 109
###begin article-title 110
Complex modulation of cell type-specific signaling in response to type I interferons
###end article-title 110
###begin article-title 111
###xml 93 97 <span type="species:ncbi:10090">mice</span>
IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice
###end article-title 111
###begin article-title 112
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Deficiency of the type I interferon receptor protects mice from experimental lupus
###end article-title 112
###begin article-title 113
Significance analysis of microarrays applied to the ionizing radiation response
###end article-title 113
###begin article-title 114
Cluster analysis and display of genome-wide expression patterns
###end article-title 114
###begin article-title 115
Java Treeview - extensible visualization of microarray data
###end article-title 115
###begin article-title 116
Protocols - The Utz Lab - Stanford University School of Medicine
###end article-title 116
###begin article-title 117
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane
###end article-title 117
###begin article-title 118
Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus
###end article-title 118
###begin article-title 119
FcgammaRIV: a novel FcR with distinct IgG subclass specificity
###end article-title 119
###begin article-title 120
Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6
###end article-title 120
###begin article-title 121
###xml 118 125 118 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo
###end article-title 121
###begin article-title 122
A novel two-color Fab labeling method for autoantigen protein microarrays
###end article-title 122
###begin article-title 123
Autoantigen arrays for multiplex analysis of antibody isotypes
###end article-title 123
###begin article-title 124
###xml 73 79 <span type="species:ncbi:10090">murine</span>
Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus
###end article-title 124
###begin article-title 125
Autoantigen microarrays for multiplex characterization of autoantibody responses
###end article-title 125
###begin article-title 126
Multiplexed protein array platforms for analysis of autoimmune diseases
###end article-title 126
###begin article-title 127
Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN
###end article-title 127
###begin article-title 128
Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity
###end article-title 128
###begin article-title 129
Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family
###end article-title 129
###begin article-title 130
###xml 44 50 <span type="species:ncbi:10090">murine</span>
A novel type I IFN-producing cell subset in murine lupus
###end article-title 130
###begin article-title 131
Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies
###end article-title 131
###begin article-title 132
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
###end article-title 132
###begin article-title 133
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
###end article-title 133
###begin article-title 134
Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology
###end article-title 134
###begin article-title 135
###xml 77 81 <span type="species:ncbi:10090">mice</span>
Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice
###end article-title 135
###begin article-title 136
Impaired clearance of dying cells in systemic lupus erythematosus
###end article-title 136

